TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02737878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance and Tone Training
Description: Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Study: NCT00350402

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle strength training
Description: The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Respiratory muscle strength training
Description: The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
Study: NCT00809965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg
Description: One tablet twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Description: One tablet twice daily
Study: NCT02737878

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance and Tone Training
Description: Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance and Tone Training
Description: Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Study: NCT00809965

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet twice daily
Study: NCT02737878

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance and Tone Training
Description: Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Study: NCT01130558

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Management
Description: Using electronic insulin order template for basal-bolus insulin and education
Study: NCT00809965

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Study: NCT03572023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrative characterization of MINOCA patients
Description: Characterization of MINOCA patients will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Characterization of MI patients with coronary obstruction
Description: Characterization of patients with myocardial infarction and obstructive atherosclerosis will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests.
Study: NCT03330418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Starting with the forty-ninth dose,the trial went into the open phase. All participants were treated with the test drugs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160 mg
Description: In the Phase B,the researchers can adjust the dose of RC18 according to the subjects' willingness and recurrence, but the maximum dose of single dose should not exceed 320g.
Study: NCT00809965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Study: NCT02032355

Intervention type: PROCEDURE
Intervention: spinal anesthesia
Study: NCT01477814

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician chart reminder
Description: Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician chart reminder
Description: Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician chart reminder
Description: Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: chart reminder, educational mat'ls, FIT
Description: Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CR,ed mat'ls, FIT, phone call
Description: Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet. Subjects will also receive a telephone call from project staff to assess barriers to screening and to encourage CRC screening
Study: NCT05271136

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-aging Serum
Description: Serum composed of a patent-pending botanical extract, bioavailable peptides, antioxidants, post-biotics, and short and long-term moisturizers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-aging Serum
Description: Serum composed of a patent-pending botanical extract, bioavailable peptides, antioxidants, post-biotics, and short and long-term moisturizers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Moisturizer
Description: Anti-aging facial moisturizer to be used by study participants after serum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cleansing Lotion
Description: Facial cleansing lotion to be used by study participants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cleansing Lotion
Description: Facial cleansing lotion to be used by study participants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen to be applied after application of serum in the morning. Participants were asked to reapply every 2 hours
Study: NCT04076033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional compressive bandage
Description: The functional compressive bandage is being performed with the volunteer sitting with the upper limb homolateral to the surgery supported by a support. After hydration of the limb, a cotton mesh is being used to prevent friction of the 1 cm density foam band being wrapped around the limb. No therapeutic procedure is being performed prior to functional compressive bandage.~The bandage of the limb is being performed with 5 cm, 10 cm, 15 cm elastic cotton bandages from the fingers to the axillary region in four layers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional compressive bandage
Description: The functional compressive bandage is being performed with the volunteer sitting with the upper limb homolateral to the surgery supported by a support. After hydration of the limb, a cotton mesh is being used to prevent friction of the 1 cm density foam band being wrapped around the limb. No therapeutic procedure is being performed prior to functional compressive bandage.~The bandage of the limb is being performed with 5 cm, 10 cm, 15 cm elastic cotton bandages from the fingers to the axillary region in four layers.
Study: NCT02743962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Wand
Description: The therapeutic wand will be used to apply a gentle caudad pressure on the pelvic floor, encouraging a release and gentle stretch of the muscles. The participants will follow a protocol of sweeping gently along one side then the other to find tender or tight areas, and then to apply the wand to relax and stretch the muscles for up to 5 minutes in total, twice weekly for the duration of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy control
Description: This group will receive standard specialist physiotherapy intervention for bladder pain syndrome as stated in the arm descriptor, and will not use the therapeutic wand.
Study: NCT00166166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetraethylammonium (TEA)
Description: 5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetraethylammonium (TEA)
Description: 5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NG-monomethyl Arginine (L-NMMA)
Description: 5 minute intra-arterial infusion of L-NMMA 8 μmol/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NG-monomethyl Arginine (L-NMMA)
Description: 5 minute intra-arterial infusion of L-NMMA 8 μmol/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradykinin
Description: Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradykinin
Description: Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Description: Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Description: Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
Study: NCT01663519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Custom made insoles 35 shore
Description: Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prefabricated insoles
Description: Prefabricated insoles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 55 shore Custom made insole
Description: Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
Study: NCT02692105

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low dose rate prostate brachytherapy
Description: Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose Rate prostate brachytherapy
Description: Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
Study: NCT03699293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib 200mg capsule
Description: celecoxib 200mg twice a day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen sodium 550mg tablet
Description: naproxen sodium 550mg twice a day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81mg tablet
Description: 81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81mg tablet
Description: 81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period
Study: NCT00149838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prefrontal rTMS
Description: Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prefrontal rTMS
Description: Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Regimen
Description: Particpants who acheive remission with rTMS may start antidepressant medication in phase III.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Stimulation
Description: The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
Study: NCT00411138

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
Study: NCT02886637

Intervention type: OTHER
Intervention: None intervention
Study: NCT00345761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
Study: NCT04951518

Intervention type: OTHER
Intervention: VAN Stroke Scale
Description: V.A.N Stroke Assessment measures unilateral weakness with visual deficits, aphasia, and neglect in possible stroke patients

Intervention type: OTHER
Intervention: VAN Stroke Scale
Description: V.A.N Stroke Assessment measures unilateral weakness with visual deficits, aphasia, and neglect in possible stroke patients
Study: NCT00552552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue Patient Education Program (FIBS)
Description: 6 weekly sessions, 90 min each

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fatigue Patient Education Program (FIBS)
Description: Participation in the program after the second follow-up
Study: NCT03309579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberal RBC Transfusion Strategy
Description: RBC transfusion is triggered by a Hemoglobin value of ≤100g/L

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive RBC Transfusion Strategy
Description: Optional RBC transfusion is triggered by a Hemoglobin value of ≤80g/L
Study: NCT04577014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)
Study: NCT00499044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDR Computerized Cognitive Assessment System
Description: Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MATRICS Consensus Cognitive Battery
Description: The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
Study: NCT05271136

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen to be applied after application of facial moisturizer in the morning. Participants were asked to reapply every 2 hours
Study: NCT03676166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Inhaled cannabis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Inhaled cannabis